Compare Adaptive Biotechnologies Corp (ADPT) vs Okta, Inc. (OKTA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Okta, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Okta, Inc. trades at $145.94 (market cap $25.81B). The key difference: Okta, Inc. is far larger — about 7.8× Adaptive Biotechnologies Corp's market cap, and Okta, Inc. is trading nearer its 52-week high, Adaptive Biotechnologies Corp nearer its low. Which is the better fit depends on your goals.
| ADPT | OKTA | |
|---|---|---|
Market Cap | $3.33B | $25.81B |
Sector | Health | Technology |
52-Week High | $22.37 | $148.60 |
52-Week Low | $10.24 | $62.93 |
Enterprise Value | $3.19B | $23.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
OKTA trades at $148.47, up 4.99% on the day, with strong technical momentum and bullish moving averages. The company reported revenue of $2.61B in 2025, achieving profitability with net income of $28M after years of losses. Recent earnings beats and AI-driven demand have fueled investor optimism, though valuation multiples remain elevated.
Outlook is positive with robust revenue growth and improving margins, but high P/E of 107.68 poses valuation risk. Analyst consensus is bullish with 72.55% buy ratings, though price target of $121.08 suggests caution near current levels. Key risks include competition and execution on AI monetization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
